A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: A Canadian multicenter study

Journal of Allergy and Clinical Immunology

Volumn 99, Issue 1 I, 1997, Pages 13-21

  Boulet, L P ^a   Laviolette, M ^a   Boucher, S ^a   Knight, A ^a   Hebert, J ^a   Chapman, K R ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Asthma; salbutamol; salmeterol; 2 agonists

Indexed keywords

SALBUTAMOL; SALMETEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; BRONCHODILATING ACTIVITY; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; HEADACHE; HEART ARRHYTHMIA; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MULTICENTER STUDY; MUSCLE WEAKNESS; NAUSEA; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SLEEP DISORDER; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

EID: 0031032444     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(97)70295-1     Document Type: Article

References (39)

1. 2-agonist with prolonged duration of action Lung 171 1993 249 264
2. RN Brogden D Faulds Salmeterol xinafoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease Allergol et Immunopathol 20 1992 72 84
3. LP Boulet Long- versus short-acting β2-agonists. Implications for drug therapy Drugs 47 1994 207 222
4. A Ullman N Svedmyr Salmeterol, a new long acting inhaled β2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients Thorax 43 1988 674 678
5. A Ullman J Hedner N Svedmyr Inhaled salmeterol and salbutamol in asthmatic patients: an evaluation of asthma symptoms and the possible development of tachyphylaxis Am Rev Respir Dis 142 1990 571 575
6. A Cartier H Ghezzo J L'Arch|$$|Axeveque C Trudeau JL Malo Duration and magnitude of action of 50 and 100 μg of inhaled salmeterol in protecting against bronchoconstriction induced by hyperventilation of dry cold air in subjects with asthma J Allergy Clin Immunol 92 1993 488 492
7. D Nowak R Jorres KF Rabe Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours Eur J Clin Pharmacol 43 1992 591 596
8. DM Newnham CG Ingram J Earnshaw JBD Palmer DP Dhillon Salmeterol provides prolonged protection against exercise-induced bronchoconstriction in a majority of subjects with mild, stable asthma Respir Med 87 1993 439 444
9. SD Anderson LT Rodwell J Du Toit IH Young Duration of protection by inhaled salmeterol in exercise-induced asthma Chest 100 1991 1254 1260
10. EY Derom RA Pauwels MEF Van Der Straeten The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours J Allergy Clin Immunol 89 1992 811 815
11. FER Simons NR Soni WTA Watson AB Becker Bronchodilator and bronchoprotective effects of salmeterol in young patients with asthma J Allergy Clin Immunol 90 1992 840 846
12. AAPH Verberne WCJ Hop AB Bos KF Kerribijn Effect of a single dose of inhaled salmeterol on baseline airway caliber and methacholine-induced airway obstruction in asthmatic children J Allergy Clin Immunol 91 1993 127 134
13. H Campos-Gongora AFZ Wisniewski AE Tattersfield A single-dose comparison of inhaled albuterol and two formulations of salmeterol on airway reactivity in asthmatic subjects Am Rev Respir Dis 144 1991 626 629
14. OP Twentyman JP Finnerty A Harris J Palmer ST Holgate Protection against allergen-induced asthma by salmeterol Lancet 336 1990 1338 1342
15. 4 excretion J Allergy Clin Immunol 89 1992 575 583
16. B Pedersen R Dahl BB Larsen P Venge The effect of salmeterol on the early- and late-phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X Allergy 48 1993 377 382
17. R Dahl J Earnshaw JBD Palmer Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease Eur Respir J 4 1991 1178 1184
18. J Palmer ME Hyland Salmeterol in clinical practice: comparator and safety studies, quality of life studies Eur Respir Rev 1 1991 301 303
19. DS Pearlman P Chervinsky C La Force JM Seltzer DL Southern JP Kemp A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma N Engl J Med 327 1992 1420 1425
20. MG Britton JS Earnshaw JBD Palmer A twelve month comparison of salmeterol with salbutamol in asthmatic patients Eur Respir J 5 1992 1062 1067
21. B Lundback DW Rawlinson JBD Palmer Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients Thorax 48 1993 148 153
22. MF Fitzpatrick T Mackay H Driver NJ Douglas Salmeterol in nocturnal asthma: a double-blind, placebo-controlled trial of a long-acting inhaled β2-agonist BMJ 301 1990 1365 1368
23. GE D'Alonzo RA Nathan S Henochowicz RJ Morris P Ratner SI Rennard Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma JAMA 271 1994 1412 1416
24. JBD Palmer AM Stuart GL Shepherd K Viskum Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease: a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100 μg) with salmeterol (50 μg) Respir Med 86 1992 409 417
25. G Polgar V Promadhat Pulmonary function testing in children: techniques and standards 1971 Saunders Philadelphia
26. RO Crapo AH Morris RM Gardner Reference spirometric values using techniques and equipment that meet ATS recommendations Am Rev Respir Dis 123 1981 659 664
27. SAS Institute Inc SAS/STAT\\R Users Guide. Version 6 4th ed 1989 SAS Institute Inc Cary, NC
28. PH van Elteren On the combination of independent two-sample tests of Wilcoxon Bull Int Stat Inst 37 part 3 1958 351 361
29. F Wilcoxon Individual comparisons by ranking methods Biometrics 1 1945 80 83
30. 2-agonist in asthma: effects on exacerbations and lung function Thorax 48 1993 134 138
31. 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma N Engl J Med 327 1992 1198 1203
32. U.S. Department of Health and Human Services Public Health Service. International Asthma Management Project. International Consensus Report on Diagnosis and Treatment of Asthma 1992 National Institutes of Health Bethesda 1 72
33. R Ellul-Micaleff FF Fenech Effect on intravenous prednisolone in asthmatics with diminished adrenergic responsiveness Lancet 2 1975 1269 1271
34. KKP Hui ME Conolly DP Tashkin Methylprednisolone reverses the β-agonist-induced decrease in β-receptor number in human lymphocytes Clin Pharmacol Ther 32 1982 56
35. JW Jenne A critique of dosing strategies for β2-adrenergic agents and theophylline Lung 159 1987 295 314
36. MR Sears DR Taylor CG Print DC Lake Q Li EM Flannery Regular inhaled beta-agonist treatment in bronchial asthma Lancet 336 1990 1391 1396
37. WO Spitzer S Suissa P Ernst RI Horvitz B Habbick D Cockcroft The use of β -agonists and the risk of death and near death from asthma N Engl J Med 326 1992 501 506
38. KR Chapman S Kesten JP Szalai Regular vs. as-needed salbutamol in asthma control Lancet 343 1994 1372 1379
39. 2-agonists with steroids are not harmful in stable asthma J Allergy Clin Immunol 93 1994 80 84